Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Portfolio Pulse from
Milestone Pharmaceuticals has reported its Q4 and full-year 2024 financial results. The FDA has set a PDUFA review goal date of March 27, 2025, for Milestone's CARDAMYST™ (etripamil) nasal spray, which is intended for the treatment of Paroxysmal Supraventricular Tachycardia (PSVT).
March 13, 2025 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Milestone Pharmaceuticals has announced its financial results for Q4 and full-year 2024. The FDA has set a PDUFA date for its CARDAMYST™ nasal spray for PSVT on March 27, 2025, which could significantly impact the company's future revenue.
The announcement of the FDA PDUFA date for CARDAMYST™ is a significant regulatory milestone for Milestone Pharmaceuticals. If approved, the product could lead to increased revenue, positively impacting the stock price. The financial results provide context but the regulatory update is the key driver.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100